HealthLinx Limited (HTX) has expanded its collaboration with the University of Liverpool to assess the utility of its proprietary biomarkers for other indications. The expanded collaboration will have the University of Liverpool provide HealthLinx with blood samples for specific diseases where HealthLinx will run its proprietary biomarkers across these samples to determine their potential for future pipelines.
“The opportunity to expand our collaboration with Liverpool presents the company with an excellent opportunity to identify additional diseases that we may target to develop new diagnostics similar to OvPlexTM,” says Nick Gatsios Managing Director of HealthLinx. “The high mortality associated with cancers such as ovarian cancer is in part due to the failure of the current generation of diagnostic tools. It is far too common for cancer sufferers to be diagnosed with advanced disease when prognosis is poor,” says Nick Gatsios managing director. “A realistic and pragmatic way to win the fight against cancer is to substantially improve our diagnostic tools. We have made great progress in ovarian cancer and perhaps this collaboration can broaden our success with other cancers.”
Under the current collaboration agreement with the University of Liverpool, HealthLinx is licensed in key biomarkers that appear to have utility in the future development of OvPlexTM ovarian cancer diagnostic. The University of Liverpool and the Liverpool Hospital are also trial partners for the upcoming biomarker trial that will screen 1150 samples collected in Australia, Singapore and the UK. This study is a multi centre multi site study that has been designed to determine the diagnostic performance of the OvPlexTM panel and validate additional biomarkers to target ovarian cancer. HealthLinx specialises in developing new generation diagnostic blood tests to detect cancers. OvPlexTM, the Company’s first product, has been released to the market. OvPlexTM is an ovarian cancer diagnostic that has a diagnostic efficiency of 92% for early stage ovarian cancer. This product is now available in Australia and in February 2010 the product will be launched in the UK and Ireland with other countries following over the next twelve months.
HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. Commercial sales of the OvPlex test have begun in Australia and are soon to commence in the UK. HealthLinx is developing new and increasingly accurate next generation diagnostics and will seek license partners to roll out worldwide sales.
www.healthlinx.com.au
